Progestin-primed Ovarian Stimulation With Clomiphene Citrate Compared With the Standard Progestin-primed Ovarian Stimulation in Various Aged Women With Diminished Ovarian Reserve: a Retrospective Study

Yue Lin
The First Affiliated Hospital of Wenzhou Medical University

Qianqian Chen
The First Affiliated Hospital of Wenzhou Medical University

Jing Zhu
The First Affiliated Hospital of Wenzhou Medical University

Yili Teng
The First Affiliated Hospital of Wenzhou Medical University

Xuefeng Huang
The First Affiliated Hospital of Wenzhou Medical University

Xia Chen (chenxia96sz@163.com)
The First Affiliated Hospital of Wenzhou Medical University

Research

Keywords: Diminished ovarian reserve, Progestin-primed ovarian stimulation, Clomiphene citrate, In vitro fertilization

DOI: https://doi.org/10.21203/rs.3.rs-864573/v1

License: © This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License
Abstract

Background: Clomiphene citrate (CC) supplementation in the progestin-primed ovarian stimulation (PPOS) protocol effectively alleviated profound pituitary suppression from progestin administration and reduced the gonadotropin (Gn) dose in the population of women with normal-ovarian-reserve or polycystic ovarian syndrome. Limited data are available about the role of CC in PPOS for women with diminished ovarian reserve (DOR). This study aimed to compare the efficiency of the PPOS protocol with CC supplementation and the standard PPOS protocol for various aged women with DOR.

Methods: A total of 364 patients with DOR were recruited for this retrospective cohort study. They were divided into subgroups based on female age, ≤35 years and ≥35 years. The clinical characteristics and outcome were compared between the groups in subgroups.

Results: In all patients with DOR, the PPOS protocol with CC supplementation was associated with a lower percentage of women with profound pituitary suppression (0.0% vs 18.6%, P = 0.001 and 1.3% vs 11.0%, P = 0.002) and a higher mean luteinizing hormone (LH) level during controlled ovarian stimulation (COS) than the standard PPOS protocol (P < 0.05). In young women with DOR, more number of high-quality cleavage-stage embryos (1.96 vs. 1.38, P = 0.018) was achieved in the PPOS protocol with CC supplementation. In elderly women with DOR, PPOS protocol with CC supplementation led to an increase in the incidence of LH levels above 10 IU/L on the trigger day (12.7% vs. 4.9%, P = 0.028) and decrease in the rate of oocyte maturation (84.7% vs. 89.9%, P = 0.034) compared to the standard PPOS protocol. No significant differences were observed in the Gn duration, total dosage of Gn, and pregnancy outcomes between the groups.

Conclusions: CC is an effective adjuvant to alleviate pituitary suppression in the PPOS protocol. For young women with DOR, CC supplementation has a positive impact on the number of high-quality embryos in PPOS protocol. However, elderly patients with DOR would be at risk of developing premature LH surge and poor oocyte maturation rate after the PPOS protocol with CC supplementation was applied.

Introduction

In assisted reproduction technologies (ART), the number of retrieved oocytes largely depends on a woman's ovarian reserve. Diminished ovarian reserve (DOR), which can be age dependent or independent, are manifested mainly as decreased anti-Müllerian hormone (AMH) and low antral follicle count (AFC) [1]. Patients with DOR may be at risk of poor ovarian response, especially in women aged 35 to 40 [2]. A low or poor ovarian response often results in cycle cancellation, poor outcomes, and consequent stress and disappointment to the couple. Such patients could benefit from counseling regarding protocol selection to improve the clinical outcomes [3]. Therefore, clinicians and researchers worldwide are seeking a proper controlled ovarian stimulation (COS) protocol for patients with DOR.

Progestin-primed ovarian stimulation (PPOS) has been approved its effective in preventing an endogenous luteinizing hormone (LH) surge during COS [4–7]. But the continuous supply of progestin during PPOS can lead to profound pituitary suppression [4–6]. It was reported that profound pituitary suppression was positively correlated with the gonadotropin (Gn) duration [5]. Clomiphene citrate (CC) was used to block negative feedback trigged by estrogen, thereby resulting in elevated follicle-stimulating hormone and LH release from the hypothalamus [8, 9]. PPOS supplemented with CC significantly reduced the occurrence of profound pituitary suppression in women with normal ovarian reserve or polycystic ovarian syndrome and the combination of CC and PPOS is likely to reduce the Gn duration compared to those without CC [5, 6].
Currently, limited data are available about the role of CC in PPOS for women with DOR. In addition, age is considered a marker for oocyte quality, which is correlated with embryo euploid rates in ART [10]. Therefore, the present study was designed to compare the efficiency of the PPOS protocol with CC supplementation and the standard PPOS protocol for various aged women with DOR.

**Materials And Methods**

**Study design and participants**

We conducted a retrospective cohort study at the reproductive medicine center of the First Affiliated Hospital of Wenzhou Medical University. From June 2018 to February 2020, women with two or more of the following items were diagnosed with DOR: (a) FSH ≥ 10IU; (b) FSH/LH ≥ 2; (c) AFC ≤ 8; and (d) AMH ≤ 1.1. Both in vitro fertilization (IVF) and intracytoplasmic sperm injection (ICSI) cycles were included. Women who were diagnosed with uterine cavity abnormalities, untreated hydrosalpinx, and immunologic disease were excluded. Every woman contributed to the study with a single stimulation cycle only. In women with multiple treatment cycles, the chronologically first cycle was chosen. For analysis, couples were grouped as follows: patients using PPOS protocol with CC supplementation were grouped into the “PPOS with CC group”, while patients using standard PPOS protocol were grouped into the “standard PPOS group”. Subpopulations of patients were characterized by different ranges of age, ≤35 years and 35 years. All data were retrospectively collected from computer databases and stored in a deidentified database. Permission for this study was given from the ethics committee of the First Affiliated Hospital of Wenzhou Medical University (no. 2020–02).

**Stimulation protocols and pituitary suppression**

In the PPOS with CC group, HMG (Shanghai Livzon Pharmaceutical Company, Zhuhai, China) 150-225 IU, CC (Codital Synto Limited, Limassol, France) 100 mg and MPA (Shanghai Xinyi Pharmaceutical Co., China) 10 mg daily were administered from menstrual cycle day 2-3 (MC2-3) or after an episode of withdrawal bleeding. In standard PPOS group, HMG 150-225 IU and MPA 10 mg daily were initiated from menstrual cycle day 2-3 (MC2-3) or after an episode of withdrawal bleeding. The initial dose of Gn (150-225 IU) was based on patient’s age, basic FSH, AFC, and previous promotion plan. Follicle monitor and hormone assay (FSH, LH, E₂ and P) were performed 5 days later. The dose of Gn was adjusted according to follicle development and MPA dose was consistent up to the trigger day. When the dominant follicle diameter reached ≥17 mm and the majority of growing follicles, if there were any, reached 14mm or more, recombinant human chorionic gonadotropin (Ovitrelle, Serono, Bari, Italy) were administered to trigger ovulation. Oocytes were retrieved 36 to 38 hours later. All follicles larger than 10 mm in diameter were aspirated.

Fertilization was carried out in vitro after oocyte retrieval depending on the semen parameters and previous fertilization situation. Embryos were examined for the number or regularity of blastomeres and the degree of fragmentation. One or two high-quality cleavage-stage embryos (7-9 cells and ≤20% fragmentation) were frozen via vitrification on the 3rd day after oocyte retrieval, and remaining embryos were placed in extended culture [11, 12]. Subsequently, blastocysts with good morphological grades were frozen on day 5 or 6 of culture.

**Hormone measurement**

Serum FSH, LH, E₂, and P were measured on menstrual cycle day 2-3, day 7-10, and the trigger day. Hormone levels were determined with immunofluorescence assay (Roche Diagnostics, Mannheim, Germany). The lower limits of
sensitivity were as follows: FSH 0.06 IU/L, LH 0.09 IU/L, E\textsubscript{2} 10 pg/ml and P 0.1 ng/ml. A serum LH concentration ≥1.0 IU/L on the trigger day was set as the cut-off for profound pituitary suppression [13].

**Endometrium preparation and Frozen embryo transfer**

All patients in the present study had receivedrozen-thawed embryo transfer (FET). Hormone replacement treatment was used for endometrial preparation. Briefly, the timing of embryo transfer was scheduled on the 3rd or the 5th day after progestin administration depending on the embryo stage. Embryo transfer was all conducted via the guidance of abdominal ultrasound in our center. Each patient received no more than two embryos at one time. Patients received luteal support after embryo transfer in the form of intravaginal progestin 200mg two times daily. Once pregnancy was achieved, the luteal support was continued until 10 weeks of gestation.

**Outcome measures**

We analyzed the pregnancy outcomes of the chronologically first cycle after oocyte retrieval that transferred at least one high-quality cleavage-stage embryos or good morphology blastocysts (blastocysts better than grade 322) [11]. Clinical pregnancy was defined as the presence of fetal cardiac activity confirmed by transvaginal ultrasound. Ongoing pregnancy rate was defined as the proportion of patients with ongoing pregnancy after the gestation age of 12 weeks. The implantation rate was calculated as the number of gestational sacs visualized on transvaginal ultrasound divided by the number of transferred embryos.

**Statistical analysis**

The data were evaluated by Student’s t-test for continuous variables of normal distribution, the Mann-Whitney U-test for continuous variables of non-normal distribution, the \( \chi^2 \)-test or Fisher’s exact for categorical variables, as appropriate. All tests were two-sided, and \( P < 0.05 \) was considered statistically significant. SPSS statistical software (version 25; SPSS Inc., USA) was used for data analysis. The dynamic changes in hormones during COS were presented with a broken line graph, created by Excel.

**Results**

**Patient characteristics and cycle characteristics**

In total, 364 women were enrolled. Table 1 shows the comparison of basic patient characteristics and the cycle characteristics between ovarian stimulation groups stratified by age. No statistically significant differences were found between the groups with respect to age, duration of infertility, proportion of secondary infertility, body mass index (BMI), AMH, AFC, baseline hormones, Gn duration and total dosage of Gn (\( P > 0.05 \)).
|                          | ≤35 years                  | ³5 years                  | P-value | ≤35 years                  | ³5 years                  | P-value |
|--------------------------|---------------------------|---------------------------|---------|---------------------------|---------------------------|---------|
| PPOS with CC group       |                           |                           |                     | PPOS with CC group       |                           |         |
| (HMG/MPA/CC; n = 73)     |                           |                           |                     | (HMG/MPA/CC; n = 150)    |                           |         |
| Age (years)              | 30.82±2.66                | 30.71±3.19                | 0.825              | 40.25±3.02                | 39.90±3.31                | 0.423   |
| Duration of infertility  | 3.29±2.46                 | 3.96±2.80                 | 0.148              | 3.62±3.28                 | 4.36±4.07                 | 0.138   |
| Secondary infertility, % (n) | 64.4 (47/73)            | 69.5 (41/59)              | 0.536              | 65.3 (98/150)             | 62.2 (51/82)              | 0.634   |
| Tubal factor             | 67.1 (49/73)              | 50.8 (30/59)              |                     | 61.33 (92/150)            | 62.2 (51/82)              |         |
| Male factor              | 56.16 (41/73)             | 37.3 (22/59)              |                     | 52 (78/150)               | 47.6 (39/82)              |         |
| Other factors            | 17.8 (13/73)              | 8.5 (5/59)                |                     | 16.7 (25/150)             | 15.9 (13/82)              |         |
| Unknown factor           | 13.7 (10/73)              | 11.9 (7/59)               |                     | 6.7 (10/150)              | 11.0 (9/82)               |         |
| Failed cycles            | 1.81±1.45                 | 2.11±1.37                 | 0.226              | 1.77±1.52                 | 2.07±1.65                 | 0.164   |
| BMI (kg/M²)              | 22.47±3.58                | 21.39±3.14                | 0.067              | 22.56±2.69                | 22.17±2.75                | 0.295   |
| AMH (ng/ml)              | 0.88±0.61                 | 0.95±0.64                 | 0.530              | 0.88±0.58                 | 0.86±0.49                 | 0.785   |
| Antral follicle counts   | 6.22±2.08                 | 6.15±2.03                 | 0.854              | 5.69±2.25                 | 6.01±2.31                 | 0.298   |
| Baseline hormones        |                           |                           |                     |                           |                           |         |
| FSH (IU/L)               | 11.13±5.33                | 11.23±4.18                | 0.904              | 11.10±5.02                | 12.19±4.96                | 0.116   |
| LH (IU/L)                | 4.49±2.45                 | 4.13±2.05                 | 0.370              | 4.22±2.22                 | 4.68±2.29                 | 0.131   |
| E₂ (pg/ml)               | 53.44±34.97               | 53.29±29.55               | 0.980              | 58.57±44.35               | 59.78±45.34               | 0.843   |
| P (ng/ml)                | 0.55±0.31                 | 0.60±0.41                 | 0.380              | 0.52±0.46                 | 0.51±0.40                 | 0.848   |
| Gn duration (days)       | 9.32±2.45                 | 9.90±3.75                 | 0.284              | 9.71±2.28                 | 10.05±3.06                | 0.386   |
| Total dosage of Gn (IU)  | 1975.34±555.86            | 2052.54±1448.86           | 0.700              | 2050.53±575.89            | 1993.29±971.05            | 0.626   |
| Percentage of women with profound pituitary suppression, % (n) | 0.0 (0/73) | 18.6 (11/59) | <0.001 | 1.3 (2/150) | 11.0 (9/82) | 0.002 |
|---|---|---|---|---|---|---|
| Incidence of LH level ≥10 IU/L on the trigger day, % (n) | 9.6 (7/73) | 3.4 (2/59) | 0.187 | 12.7 (22/150) | 4.9 (4/82) | 0.028 |

CC, clomiphene citrate; PPOS, progestin-primed ovarian stimulation; MPA, medroxyprogesterone acetate; BMI, body mass index; AMH, anti-Müllerian hormone; AFC, antral follicle count; FSH, follicle-stimulating hormone; LH, luteinizing hormone; E2, estradiol; P, progesterone; Gn, gonadotropin; ND, not defined.

a Because someone may have more than 1 cause of infertility.

**Controlled ovarian stimulation and embryological outcomes**

The COS and embryological outcomes of both groups are presented in Table 2. There was no statistical difference found in 2PN rate and number of 2PN cleavage between the groups. No difference was observed in the cancellation rate prior to oocyte retrieval (P ≥ 0.05). For women aged above 35 years, the mean number of oocytes retrieved in PPOS with CC group was significantly higher than those in standard PPOS group (4.23 vs. 3.50, P = 0.034). However, the oocyte maturation rate in PPOS with CC group was significantly lower than those in standard PPOS group (84.7% vs. 89.9%, P = 0.034). Compared with women aged below 35 years in standard PPOS group, a significantly higher number of high-quality cleavage-stage embryos and a significantly lower no high-quality cleavage-stage embryos cycles rate were noted in PPOS with CC group (1.96 vs. 1.38, P ≥ 0.018 and 11.0% vs 33.9%, P ≥ 0.001, respectively), while no difference was found in the other subgroups.
Table 2
Clinical outcomes between groups stratified by age.

|                      | ≤ 35 years | > 35 years | P-value | ≤ 35 years | > 35 years | P-value |
|----------------------|------------|------------|---------|------------|------------|---------|
|                      | PPOS with CC group | Standard PPOS group |          | PPOS with CC group | Standard PPOS group |          |
|                      | (HMG/MPA/CC; n = 73) | (HMG/MPA; n = 59) |          | (HMG/MPA/CC; n = 150) | (HMG/MPA; n = 82) |          |
| No. of >14mm follicles on trigger day | 4.34 ± 2.29 | 3.20 ± 1.57 | 0.001 | 3.51 ± 1.89 | 3.28 ± 1.93 | 0.374 |
| No. of oocytes retrieved | 5.10 ± 2.72 | 4.44 ± 3.97 | 0.264 | 4.23 ± 2.64 | 3.50 ± 2.16 | 0.034 |
| ICSI MII oocytes rate, % (n) | 87.3 (165/189) | 80.0 (56/70) | 0.140 | 82.5 (274/332) | 88.3 (121/137) | 0.118 |
| Oocyte maturation rate, % (n) | 85.2 (317/372) | 82.8 (217/262) | 0.416 | 84.7 (537/634) | 89.9 (258/287) | 0.034 |
| 2PN rate of IVF oocytes, % (n) | 78.9 (120/152) | 72.0 (116/161) | 0.157 | 70.7 (186/263) | 79.6 (109/137) | 0.057 |
| 2PN rate of ICSI oocytes, % (n) | 79.4 (131/165) | 82.1 (46/56) | 0.656 | 80.7 (221/274) | 79.3 (96/121) | 0.762 |
| No. of 2PN cleavage | 3.54 ± 2.17 | 2.89 ± 2.00 | 0.089 | 2.75 ± 1.82 | 2.55 ± 1.57 | 0.407 |
| No. of high-quality cleavage-stage embryos | 1.96 ± 1.44 | 1.38 ± 1.26 | 0.018 | 1.47 ± 1.28 | 1.46 ± 1.28 | 0.983 |
| No high-quality cleavage-stage embryos cycles rate, % (n) | 11.0 (8/73) | 33.9 (20/59) | 0.001 | (38/150) | (19/82) | 0.715 |
| Cancellation rate prior to oocyte retrieval, % (n) | 2.7 (2/73) | 0.0 (0/59) | 0.502 | 0.0 (0/150) | 2.4 (2/82) | 0.124 |
| FET cycles | 56 | 35 | 92 | 57 |
| No. of transferred embryos | 1.86 ± 0.35 | 1.74 ± 0.44 | 0.202 | 1.79 ± 0.41 | 1.79 ± 0.41 | 0.954 |
| Endometrial thickness (mm) | 9.86 ± 1.87 | 9.37 ± 1.89 | 0.233 | 9.69 ± 1.86 | 9.21 ± 1.69 | 0.119 |
| Clinical pregnancy rate, % (n) | 44.6 (25/56) | 54.3 (19/35) | 0.371 | 35.9 (33/92) | 28.1 (16/57) | 0.325 |
| Ongoing pregnant rate, % (n) | 39.3 (22/56) | 51.4 (18/35) | 0.256 | 22.8 (21/92) | 17.5 (10/57) | 0.440 |
| Implantation rate, % (n) | 29.8 (31/104) | 41.0 (25/61) | 0.143 | 21.8 (36/165) | 17.6 (18/102) | 0.410 |
| Miscarriage rate, % (n) | 12.0 (3/25) | 5.3 (1/19) | 0.622 | 36.4 (12/33) | 25.0 (4/16) | 0.526 |

CC, clomiphene citrate; PPOS, progestin-primed ovarian stimulation; MPA, medroxyprogesterone acetate; No., number; ICSI, Intracytoplasmic sperm injection; FET, frozen-thawed embryo transfer; ND, not defined.

*Because someone may have more than 1 cause of infertility.*
|                | ≤ 35 years | > 35 years |
|----------------|------------|------------|
| Ectopic pregnancy rate, % (n) | 0 (1/33)   | 6.3 (1/16) |
| Live birth, % (n) | 39.3 (22/56) | 21.7 (20/92) |

CC, clomiphene citrate; PPOS, progestin-primed ovarian stimulation; MPA, medroxyprogesterone acetate; No., number; ICSI, Intracytoplasmic sperm injection; FET, frozen-thawed embryo transfer; ND, not defined.

\( ^a \) Because someone may have more than 1 cause of infertility.

**Hormone profile during treatment**

The serum concentrations of FSH, LH, E\(_2\) and P in the two groups stratified by age are presented in Figure 1. In both groups, the FSH levels increased after Gn administration, and no difference was found between the groups (\( P \geq 0.05 \)). The serum E\(_2\) levels and P levels increased gradually in both groups after Gn administration. The serum E\(_2\) levels and P levels on day of trigger in the PPOS with CC group were significantly higher than those in all subgroups of the standard PPOS group (1974.68±1239.05 pg/ml vs. 1143.19±742.72 pg/ml, \( P \leq 0.001 \), 1777.37±1148.10 pg/ml vs. 1220.22±796.84 pg/ml, \( P \leq 0.001 \), 1.02±0.50 ng/ml vs. 0.83±0.53 ng/ml, \( P \leq 0.043 \), 0.99±0.87 ng/ml vs. 0.69±0.40 ng/ml, \( P \leq 0.001 \), respectively).

The LH levels of the two groups showed different trends. The LH levels in the PPOS with CC group increased first and then remained steady at a range of 5.52–6.61 IU/L; in contrast, the LH levels in the standard PPOS group remained at a certain level initially and then slightly decreased. There was no significant difference in the value of basal LH between the groups (\( P \geq 0.05 \)), whereas the LH levels on day 7–10 and day of trigger in the PPOS with CC group were significantly higher than that in all subgroups of the standard PPOS group (\( P \leq 0.05 \)).

As shown in Table 1, the percentage of women with profound pituitary suppression was significantly lower in the PPOS with CC group than that in standard PPOS group (0.0% vs 18.6%, \( P \leq 0.001 \) and 1.3% vs 11.0%, \( P \leq 0.002 \)). In addition, compared with the standard PPOS group, the percentage of patients with LH levels above 10 IU/L on the trigger day was higher in the PPOS with CC group, especially for patients aged above 35 years (12.7% vs. 4.9%, \( P \leq 0.028 \)). All patients with LH levels above 10 IU/L on the trigger day confirmed the sonolucent follicles are still there by transvaginal ultrasound just before the planned oocyte retrieval and underwent oocyte retrieval, among which only two patients had no oocytes retrieved and only one patient had no mature oocytes being retrieved.

**Pregnancy outcomes**

In this study, 29 women did not complete the FET cycles for no viable embryos and 62 women for personal reasons before the end of the study. In total, 273 women completed FET cycles during the 18 months of follow-up, among which 4 women transferred with embryos collected from twice oocyte retrieval and 29 women transferred with no high-quality cleavage-stage embryos or good morphology blastocysts. The discontinuation rate of the cycle, which achieved at least one high-quality cleavage-stage embryos, was comparable between the groups (10.3% [4/39] vs 13.8% [9/65]; 9.5% [6/63] vs 17.9% [20/112]; \( P \geq 0.05 \)). Only 240 women were transferred with at least one high-quality cleavage-stage embryos or good morphology blastocysts, which were included in the analysis of pregnancy outcomes (Table 2). The rate of blastocysts transfers was similar between the groups in all subgroups (5.4% [3/56]...
vs 14.3% [5/35]; 6.5% [6/92] vs 0% [0/57]; \( P \leq 0.05 \)). The clinical pregnancy rate, ongoing pregnant rate, implantation rate, miscarriage rate, ectopic pregnancy rate and live birth rate were comparable between the groups in all subgroups (\( P \leq 0.05 \)).

All newborns were examined with no congenital malformation except that oesophageal atresia was found in one baby of the PPOS with CC group and cleft lip and palate in one baby of the standard PPOS group.

Furthermore, we assess the clinical outcomes of patients with LH levels above 1 IU/L, but below 10 IU/L on the trigger day (Table 3). We found similar trend of the outcomes in these patients as in the whole population.
Table 3
Clinical outcomes patients with LH levels above 1 IU/L, but below 10 IU/L on the trigger day between groups stratified by age.

|                          | ≤ 35 years | > 35 years | P-value | ≤ 35 years | > 35 years | P-value |
|--------------------------|------------|------------|---------|------------|------------|---------|
|                          | PPOS with CC group (HMG/MPA/CC; n = 66) | Standard PPOS group (HMG/MPA; n = 46) | P-value | PPOS with CC group (HMG/MPA/CC; n = 126) | Standard PPOS group (HMG/MPA; n = 69) | P-value |
| No. of >14mm follicles on trigger day | 4.50 ± 2.82 | 3.15 ± 1.61 | < 0.001 | 3.66 ± 1.85 | 3.51 ± 1.99 | 0.595 |
| No. of oocytes retrieved | 5.38 ± 2.59 | 4.65 ± 4.32 | 0.269 | 4.43 ± 2.67 | 3.72 ± 2.23 | 0.064 |
| ICSI MII oocytes rate, % (n) | 86.9 (159/183) | 78.3 (47/60) | 0.110 | 83.0 (230/277) | 89.5 (102/114) | 0.106 |
| Oocyte maturation rate, % (n) | 84.5 (300/355) | 81.3 (174/214) | 0.322 | 85.7 (478/558) | 90.7 (233/257) | 0.047 |
| 2PN rate of IVF oocytes, % (n) | 78.0 (110/141) | 70.1 (89/127) | 0.138 | 70.2 (174/248) | 79.4 (104/131) | 0.053 |
| 2PN rate of ICSI oocytes, % (n) | 79.2 (126/159) | 80.9 (38/47) | 0.810 | 83.0 (191/230) | 79.4 (81/102) | 0.428 |
| No. of 2PN cleavage | 3.58 ± 2.18 | 2.76 ± 2.10 | 0.051 | 2.90 ± 1.85 | 2.67 ± 1.59 | 0.383 |
| No. of high-quality cleavage-stage embryos | 2.02 ± 1.47 | 1.22 ± 1.25 | 0.003 | 1.55 ± 1.31 | 1.54 ± 1.31 | 0.954 |
| No high-quality cleavage-stage embryos cycles rate, % (n) | 9.1 (6/66) | 37.0 (17/46) | < 0.001 | 21.4 (27/126) | 18.8 (13/69) | 0.669 |
| Cancellation rate prior to oocyte retrieval, % (n) | 3.0 (2/66) | 0.0 (0/46) | 0.512 | 0.0 (0/126) | 2.9 (2/69) | 0.124 |
| FET cycles | 52 | 25 | 79 | 51 |
| No. of transferred embryos | 1.87 ± 0.35 | 1.72 ± 0.46 | 0.168 | 1.81 ± 0.40 | 1.80 ± 0.40 | 0.931 |
| Endometrial thickness (mm) | 9.90 ± 1.91 | 9.32 ± 1.94 | 0.221 | 9.89 ± 1.87 | 9.34 ± 1.73 | 0.092 |
| Clinical pregnancy rate, % (n) | 44.2 (23/52) | 56.0 (14/25) | 0.333 | 36.7 (29/79) | 29.4 (15/51) | 0.391 |
| Ongoing pregnant rate, % (n) | 38.5 (20/52) | 52.0 (13/25) | 0.261 | 21.5 (17/79) | 19.6 (10/51) | 0.793 |
| Implantation rate, % (n) | 29.9 (29/97) | 44.2 (19/43) | 0.100 | 22.4 (32/143) | 18.5 (17/92) | 0.473 |

CC, clomiphene citrate; PPOS, progestin-primed ovarian stimulation; MPA, medroxyprogesterone acetate; No., number; ICSI, intracytoplasmic sperm injection; FET, frozen-thawed embryo transfer; ND, not defined.

*Because someone may have more than 1 cause of infertility.*
|                | ≤ 35 years | > 35 years |
|----------------|-----------|-----------|
| **Miscarriage rate, % (n)** | 13.0 (3/23) | 7.1 (1/14) | 1.000 | 37.9 (11/29) | 20.0 (3/15) | 0.314 |
| **Ectopic pregnancy rate, % (n)** | 0 | 0 | ND<sup>a</sup> | 3.4 (1/29) | 6.7 (1/15) | 1.000 |
| **Live birth, % (n)** | 38.5 (20/52) | 52.0 (13/25) | 0.261 | 21.5 (17/79) | 19.6 (10/51) | 0.793 |

CC, clomiphene citrate; PPOS, progestin-primed ovarian stimulation; MPA, medroxyprogesterone acetate; No., number; ICSI, intracytoplasmic sperm injection; FET, frozen-thawed embryo transfer; ND, not defined.

<sup>a</sup> Because someone may have more than 1 cause of infertility.

**Discussion**

This retrospective cohort trial showed that the percentage of women with profound pituitary suppression was significantly lower in the PPOS with CC group than that in standard PPOS group in all subgroups. For young women with DOR, PPOS protocol with CC supplementation led to an increase in the number of high-quality cleavage-stage embryos compared to the standard PPOS protocol. For elderly patients with DOR, the efficiency of the two protocols in embryological outcomes was similar with each other, but significantly higher incidence of LH levels above 10 IU/L on the trigger day and significantly lower rate of oocyte maturation were found in the PPOS with CC group.

According to progesterone's antipositive feedback mechanism, concurrent administration of progestin with estrogen inhibited estrogen's positive feedback and therefore abolished the premature LH surge [14, 15]. Kuang et al [4] indicated that the application of progestin from the beginning of ovarian stimulation may lead to profound pituitary suppression and women in the standard PPOS protocol exhibited lower LH levels and had higher rates of profound pituitary suppression compared with the PPOS protocol with CC supplementation. According to our results, the proportion of women with profound pituitary suppression was also significantly higher in the standard PPOS protocol than in the PPOS protocol with CC supplementation in all subgroups (P<0.01). Some investigators believe that a low LH concentration results in unfavorable clinical outcomes for ovarian stimulation [16-18]. Fleming et al [16] observed that patients with very low LH concentrations (≤0.5 IU/L) tended to have a low oocyte yield and fertilization rate as well as less available embryos with the long protocol. A higher rate of pregnancy loss (45%) was documented by Westergaad et al [17] in patients with very low LH concentrations (≤0.5 IU/L). Low LH Level on the day of trigger (≤1.60 mIU/ml) was reported to be associated with reduced ongoing pregnancy and live birth rates and increased early miscarriage rates [19]. CC interacts with the hypothalamic estrogen receptors and increases endogenous FSH and LH secretion by blocking estrogen's negative feedback mechanism [8, 20, 21]. In this study, the LH levels during the COS process were higher in the PPOS with CC group in all subgroups (P<0.01). Therefore, CC supplementation alleviated profound LH suppression.

Our data showed that the LH levels on day 7–10 and day of trigger in the PPOS with CC group were significantly higher than those in all subgroups of the standard PPOS group (P<0.05). The key role of LH in synthesizing and secreting androgens, which are required for further production of E<sub>2</sub> and P, is widely acknowledged [22]. In the present study, E<sub>2</sub> levels and P levels at the time of ovulation were significantly higher in the PPOS with CC group than in the standard PPOS group (P<0.01), indicating that a high level of LH in the PPOS with CC group may further promote E<sub>2</sub> and P synthesis. According to the concept of a therapeutic window for LH, proposed by Hillier, there is a threshold requirement for LH for an optimal cycle outcome [23]. In the present study, the number of high-quality
cleavage-stage embryos was higher among younger patients treated with the PPOS protocol with CC supplementation. Whereas, HMG was used in both treatments and we noted that Gn duration, total dosage of Gn, and the FSH level during COS between the groups were similar. It was not likely that the improved embryological outcomes could be attributed to the Gn use in the PPOS with CC group. These findings further support the notion that LH plays a critical role in normal follicular development [24]. However, for elderly patients with DOR, though the number of ≥14mm follicles on trigger day was comparable between the groups (P ≥ 0.05), PPOS protocol with CC supplementation led to a decrease in the rate of oocyte maturation compared to the standard PPOS protocol. In addition, the embryological outcomes between the groups were similar in elderly patients with DOR. We found similar trend of the outcomes in patients with LH levels above 1 IU/L, but below 10 IU/L on the trigger day as in the whole population. Furthermore, the pregnancy outcomes were comparable between the groups, demonstrating a similar development potential of the embryos despite the different LH levels. Thus, our study indicated that elevated serum LH during the COS process had no impact on embryological outcomes, but might be associated with decreases in the oocyte maturation rate for elderly patients with DOR. The possible explanation is that women with DOR of different ages may require different range of therapeutic window for LH [24]. On the basis of these results, we suggest that the early stage of embryo development may differ slightly between oocytes retrieved after the PPOS protocol with CC supplementation or standard PPOS protocol was applied. Additional fundamental researches should be performed to determine the alterations in the follicular microenvironment, which may help determine the optimal range of the LH level, elucidate the mechanism by which LH affects oocyte quality and provide evidence for the use of PPOS.

Our data showed that the incidence of profound pituitary suppression was lower but the incidence of LH levels above 10 IU/L on the trigger day was higher in the PPOS with CC group, especially for patients aged above 35 years (P ≤ 0.05). Guo et al reported that higher percentage of premature LH surge (10.2%) was found in patients aged more than 35 years after the PPOS protocols using utrogestan applied [25]. Three other independent previous studies have found a similar correlation between low ovarian reserve or older age group patients and premature LH elevation [26-28]. It suggested that, though CC supplementation alleviated profound LH suppression, elderly patients with DOR would be at risk of developing premature LH surge and poor oocyte maturation rate.

Our study had several strengths as well as a few limitations. This trial fills a gap in the literature because there are relatively few published studies verifying the feasibility of CC co-administration in the PPOS protocol in various aged women with DOR. These results from a CC combination regimen may provide a new insight for develop an individualized treatment regimen for women with DOR to improve clinical outcomes. Because we used the “freeze-all” strategy, there was a waiting period between oocyte retrieval and embryo transfer. Though there are 116 extra high-quality cleavage-stage embryos or good morphology blastocysts dose not get transferred, because the cycle discontinuation rate was similar between the groups, any possible bias should be minimal.

**Conclusions**

This retrospective cohort trial demonstrated that CC supplementation could mitigate the profound LH suppression caused by progestin administration. For young women with DOR, PPOS protocol with CC supplementation led to an increase in the number of high-quality cleavage-stage embryos compared to the standard PPOS protocol. However, elderly patients with DOR would be at risk of developing premature LH surge and poor oocyte maturation rate after the PPOS protocol with CC supplementation was applied.

**Abbreviations**
Clomiphene citrate; PPOS: Progestin-primed ovarian stimulation; Gn: Gonadotropin; DOR: Diminished ovarian reserve; COS: Controlled ovarian stimulation; LH: Luteinizing hormone; ART: Assisted reproduction technologies; AMH: Anti-Müllerian hormone; FET: Frozen-thawed embryo transfer; AFC: Antral follicle count; FSH: Follicle-stimulating hormone; ICSI: Intracytoplasmic sperm injection; IVF: In vitro fertilization; MPA: Medroxyprogesterone acetate; E2: Estradiol; P: Progesterone.

Declarations

Acknowledgements

We thank the entire staff of the Reproductive Medicine Center, First Affiliated Hospital of Wenzhou Medical University, for their support in this trial.

Authors’ contributions

Yue Lin, Qianqian Chen, Xuefeng Huang and Xia Chen were the chief investigators who completed the entire study, including procedures, conception, design and completion. Jing Zhu and Yili Teng were responsible for the collection of data. Yue Lin and Qianqian Chen analysed the data and drafted the manuscript together. All authors read and approved the final manuscript.

Authors’ information

The findings and conclusions of this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.

Funding

This work was supported by the National Natural Science Foundation of China (No. 81901551).

Availability of data and materials

Data are not publicly shared; please contact the authors for data requests.

Ethics approval and consent to participate

Permission for this study was given from the ethics committee of the First Affiliated Hospital of Wenzhou Medical University (no. 2020–02). No patient consent was required for this retrospective cohort study.

Consent for publication

All authors have reviewed the manuscript and consent for publication.

Competing interests

The authors declare that they have no competing interests.

References

1. Coccia ME, Rizzello F. Ovarian reserve. Ann N Y Acad Sci 2008;1127:27–30.
2. Ferraretti AP, La Marca A, Fauser BC, Tarlatzis B, Nargund G, Gianaroli L; ESHRE working group on Poor Ovarian Response Definition. ESHRE consensus on the definition of 'poor response' to ovarian stimulation for in vitro fertilization: the bologna criteria. Hum Reprod 2011;26:1616–24.

3. La Marca A, Sunkara SK. Individualization of controlled ovarian stimulation in IVF using ovarian reserve markers: from theory to practice. Hum Reprod Update. 2014; 20(1):124–40.

4. Kuang Y, Chen Q, Fu Y, Wang Y, Hong Q, Lyu Q, et al. Medroxyprogesterone acetate is an effective oral alternative for preventing premature luteinizing hormone surges in women undergoing controlled ovarian hyperstimulation for in vitro fertilization. Fertil Steril 2015;104:62–70.e3.

5. Liu Y, Chen Q, Yu S, Wang Y, He W, Chang HY, et al. Progestin-primed ovarian stimulation with or without clomiphene citrate supplementation in normal ovulatory women undergoing in vitro fertilization/intracytoplasmic sperm injection: A prospective randomized controlled trial. Clin Endocrinol (Oxf). 2018 Mar;88(3):442-452.

6. Ye H, Tian H, He W, Lyu Q, Kuang Y, Chen Q, et al. Progestin-primed milder stimulation with clomiphene citrate yields fewer oocytes and suboptimal pregnancy outcomes compared with the standard progestin-primed ovarian stimulation in infertile women with polycystic ovarian syndrome. Reprod Biol Endocrinol. 2018 May 28;16(1):53.

7. Cai R, Zheng B, Lin Q, Deng J, Zeng X, Lin W, et al. A meta-analysis of the efficacy of progestin-primed ovarian stimulation with medroxyprogesterone acetate in ovulation induction in poor ovarian responders. J Gynecol Obstet Hum Reprod. 2020 Dec 30;50(7):102049.

8. Adashi EY. Clomiphene citrate: mechanism(s) and site(s) of action-a hypothesis revisited. Fertil Steril. 1984;42:331-344.

9. Tavaniotou A, Albano C, Smitz J, Devroey P. Effect of clomiphene citrate on follicular and luteal phase luteinizing hormone concentrations in in vitro fertilization cycles stimulated with gonadotropins and gonadotropin-releasing hormone antagonist. Fertil Steril. 2002;77:733-737.

10. Poseidon G, Alviggi C, Andersen CY, Buehler K, Conforti A, De Placido G, et al. A new more detailed stratification of low responders to ovarian stimulation: from a poor ovarian response to a low prognosis concept. Fertil Steril. 2016; 105(6):1452–3.

11. de los Santos MJ, Arroyo G, Busquet A, Calderón G, Cuadros J, Hurtado de Mendoza MV, et al. A multicenter prospective study to assess the effect of early cleavage on embryo quality, implantation, and live-birth rate. Fertil Steril. 2014 Apr;101(4):981-7.

12. Qin N, Chen Q, Hong Q, Cai R, Gao H, Wang Y, et al. Flexibility in starting ovarian stimulation at different phases of the menstrual cycle for treatment of infertile women with the use of in vitro fertilization or intracytoplasmic sperm injection. Fertil Steril. 2016 Aug;106(2):334-341.e1.

13. Dong J, Wang Y, Chai WR, Hong QQ, Wang NL, Sun LH, et al. The pregnancy outcome of progestin-primed ovarian stimulation using 4 versus 10 mg of medroxyprogesterone acetate per day in infertile women undergoing in vitro fertilisation: a randomised controlled trial. BJOG. 2017 Jun;124(7):1048-1055.

14. Dierschke DJ, Yamaji T, Karsch FJ, Weick RF, Weiss G, Knobil E. Blockade by progesterone of estrogen-induced LH and FSH release in the rhesus monkey. Endocrinology. 1973 May;92(5):1496-501.

15. Wildt L, Hutchison JS, Marshall G, Pohl CR, Knobil E. On the site of action of progesterone in the blockade of the estradiol-induced gonadotropin discharge in the rhesus monkey. Endocrinology. 1981 Oct;109(4):1293-4.

16. Fleming R, Lloyd F, Herbert M, Fenwick J, Griffiths T, Murdoch A. Effects of profound suppression of luteinizing hormone during ovarian stimulation on follicular activity, oocyte and embryo function in cycles stimulated with
purified follicle stimulating hormone. Hum Reprod. 1998 Jul;13(7):1788-92.
17. Westergaard LG, Laursen SB, Andersen CY. Increased risk of early pregnancy loss by profound suppression of luteinizing hormone during ovarian stimulation in normogonadotrophic women undergoing assisted reproduction. Hum Reprod. 2000 May;15(5):1003-8.
18. Ruvolo G, Bosco L, Pane A, Morici G, Cittadini E, Roccheri MC. Lower apoptosis rate in human cumulus cells after administration of recombinant luteinizing hormone to women undergoing ovarian stimulation for in vitro fertilization procedures. Fertil Steril. 2007 Mar;87(3):542-6.
19. Benmachiche A, Benbouhedja S, Zoghmar A, Humaidan P. Low LH Level on the Day of GnRH Agonist Trigger Is Associated With Reduced Ongoing Pregnancy and Live Birth Rates and Increased Early Miscarriage Rates Following IVF/ICSI Treatment and Fresh Embryo Transfer. Front Endocrinol (Lausanne). 2019 Sep 18;10:639.
20. Kerin JF, Liu JH, Phillipou G, Yen SS. Evidence for a hypothalamic site of action of clomiphene citrate in women. J Clin Endocrinol Metab. 1985 Aug;61(2):265-8.
21. Emons G, Ortmann O, Thiessen S, Knuppen R. Effects of estradiol and some antiestrogens (clomiphene, tamoxifen, and hydroxytamoxifen) on luteinizing hormone secretion by rat pituitary cells in culture. Arch Gynecol. 1986;237(4):199-211.
22. Hillier SG. Gonadotropic control of ovarian follicular growth and development. Mol Cell Endocrinol. 2001;179:39-46.
23. Hillier SG. Current concepts of the roles of follicle stimulating hormone and luteinizing hormone in folliculogenesis. Hum Reprod. 1994 Feb;9(2):188-91.
24. Weghofer A, Schnepf S, Barad D, Gleicher N. The impact of luteinizing hormone in assisted reproduction: a review. Curr Opin Obstet Gynecol. 2007 Jun;19(3):253-7.
25. Guo YC, Chen PY, Li TT, Jia L, Sun P, Zhu WS, et al. Different progestin-primed ovarian stimulation protocols in infertile women undergoing in vitro fertilization/intracytoplasmic sperm injection: an analysis of 1188 cycles. Arch Gynecol Obstet. 2019 Apr;299(4):1201-1212.
26. Kummer NE, Weitzman VN, Benadiva CA, Schmidt DW, Engmann LL, Nulsen JC. In vitro fertilization outcomes in patients experiencing a premature rise in luteinizing hormone during a gonadotropin-releasing hormone antagonist cycle. Fertil Steril. 2011 Jun 30;95(8):2592-4.
27. Reichman DE, Zakarin L, Chao K, Meyer L, Davis OK, Rosenwaks Z. Diminished ovarian reserve is the predominant risk factor for gonadotropin-releasing hormone antagonist failure resulting in breakthrough luteinizing hormone surges in in vitro fertilization cycles. Fertil Steril. 2014 Jul;102(1):99-102.
28. Kochhar PK, Ghosh P. Diminished Ovarian Reserve Predisposes to Premature Luteinizing Hormone Surges in Gonadotropin-Releasing Hormone Antagonist Cycles in In vitro Fertilization. J Hum Reprod Sci. 2020 Jul-Sep;13(3):191-195.

Figures
Figure 1

The dynamic changes in hormones during ovarian stimulation in the two groups stratified by age. A-D Hormone measurement for women aged ≤ 35 years, E-H Hormone measurement for women aged ≥ 35 years. *P values < 0.05.

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- renamed48e08.docx